You are here: Home: LCU Nurses Vol 1 Issue 1 : Faculty affiliations and financial disclosures

FACULTY AFFILIATIONS AND FINANCIAL DISCLOSURES

Postgraduate Institute for Medicine has a conflict of interest policy that requires course faculty to disclose any real or apparent commercial financial affiliations related to the content of their presentations/materials. It is not assumed that these financial interests or affiliations will have an adverse impact on faculty presentations; they are simply noted here to fully inform participants. The presenting faculty reported the following:

Paul A Bunn Jr, MD
Professor of Medicine and Director
University of Colorado Cancer Center
Denver, Colorado

Financial disclosure:
Grants/Research Support: Eli Lilly and Company, Pharmacia & Upjohn SpA

Consultant and Honorarium: Allos Therapeutics Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aventis Pharmaceuticals Inc, Celera Genomics, Celgene Corporation, Eli Lilly and Company, Ligand
Pharmaceuticals, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals, Pharmacia & Upjohn SpA

Karen Kelly, MD
Professor of Medicine
Director of the Clinical Thoracic Oncology Program University of Colorado Health Sciences Center Denver, Colorado

Financial disclosure:
Grants/Research Support and Honorarium:
AstraZeneca Pharmaceuticals LP
Consultant: AstraZeneca Pharmaceuticals LP,
Genentech BioOncology

 

Susie Lehnerz, BA
Clinical Research Associate
UCCC Clinical Investigations Core
Aurora, Colorado

No financial interests or affiliations to disclose


Lyn Magree, BS, CCRP
Clinical Research Associate
UCCC Clinical Investigations Core
Aurora, Colorado

No financial interests or affiliations to disclose

Tina Russell, RN, OCN
Clinical Nurse for the Lung Cancer Program
University Hospital Cancer Center
Aurora, Colorado

Financial disclosure:
Honorarium: AstraZeneca Pharmaceuticals LP


Karen J Stanley, RN, MSN, AOCN, FAAN
Nursing Consultant President-elect, Oncology Nursing Society Claremont, California

Financial disclosure:
Consultant and Honorarium: Janssen Pharmaceutica, Ortho Biotech Products LP, Pfizer Inc

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Postgraduate Institute for Medicine (PIM), Research To Practice and AstraZeneca Pharmaceuticals LP do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, Research To Practice and AstraZeneca Pharmaceuticals LP. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Table of Contents Top of Page

 
 
Table of Contents
 
Editor’s Note: A paradigm shift in oncology nursing
 
Patient Case Summaries
 
Excerpts from the Audio Program
 
 
CE Information
Faculty Disclosures
Editor's Office
Terms of use and general disclaimer
© Research To Practice 2004. All rights reserved.